TO THE EDITOR
Imatinib mesylate (Gleevec, Glivec, formerly, STI571) is an inhibitor of the BCR-ABL tyrosine kinase that is central to the pathogenesis of chronic myelogenous leukemia (CML). A recent large-scale prospective randomized trial, comparing imatinib vs interferon plus cytarabine for chronic phase CML, demonstrated the impressive therapeutic superiority of imatinib. 1 The current therapeutic strategy for CML was reviewed by Hehlmann. 2 Although imatinib is a well-tolerated drug, various adverse events such as superficial edema, nausea, muscle cramps, and skin rash were reported. These events were grades 1-2 in most cases, and medical treatment appears to be feasible. 3 With respect to the respiratory complications, dyspnea and cough have been reported to occur in 7-10 and 10-14% of patients receiving imatinib, respectively, 1,3 although they were ascribed to pulmonary edema. Their causes have not been clearly described. We report a case of an imatinib-induced interstitial pneumonia and its pathologic findings obtained by transbronchial lung biopsy (TBLB) in a patient with CML.
The patient was a 64-year-old man who was first given a diagnosis of CML in June 2001. Thereafter, he received 1000 mg of hydroxycarbamide daily, which resulted in a complete hematological response. After 18 months, his white blood cell (WBC) count increased even though he was still receiving hydroxycarbamide. No hepatosplenomegaly was noted. The bone marrow findings showed a hypercellular marrow with 1.6% blasts, and interphase-FISH analysis revealed the BCR-ABL fusion gene in 89.8% of the bone marrow nucleated cells. Imatinib (400 mg/day) was started in January 2003, resulting in a complete hematological response. However, on the 78th day after initiation of imatinib, he started to suffer dyspnea (HughJones grade II). At that time, an interphase-FISH analysis revealed the BCR-ABL fusion gene to be present in 92.5% of peripheral neutrophils. Chest X-ray showed bilateral groundglass opacities in the lower lung fields. Computed tomography (CT) revealed reticular and ground-glass opacities in the subpleural area ( Figure 1 ). Arterial blood measurements showed a pH of 7.418, arterial oxygen pressure of 95.6 mmHg, and carbon dioxide pressure of 43.3 mmHg in room air. No other symptoms, including skin rash and edema, were noted. He did not take other medicines at that time. Laboratory studies revealed that the WBC count was 3.9 Â 10 6 /l with 12.7% eosinophils, hemoglobin was 11.2 g/dl, and platelet count was 1.4 Â 10 8 /l. The erythrocyte sedimentation rate was 33 mm/h, Creactive protein was 1.4 mg/l, LDH was 438 U/l (normal range: 224 454 U/l), and KL-6, which indicates an activity of interstitial pneumonia, was 1 360 U/ml (normal limit: less than 500 U/ml), respectively. Other biochemical data were all within normal ranges. Although a drug lymphocyte-stimulating test (DLST) for imatinib mesylate was negative, imatinib-induced interstitial pneumonia was suspected, because no other cause was evident. Imatinib was discontinued after a total dose of 31 200 mg (400 mg Â 78 days). A TBLB revealed the destruction of alveolar septi and mixed intra-alveolar and interstitial fibrosis along with eosinophilic infiltration (Figure 2 ). Bronchoalveolar lavage fluid could not able to be collected at that time. After cessation of imatinib, the dyspnea improved within 10 days even without steroid therapy. Chest X-ray and CT on the 18th day after cessation of imatinib showed almost complete resolution of interstitial shadows. Since the WBC count re-elevated to 30 Â 10 6 /l after discontinuation of imatinib, we began to give hydroxycarbamide, increasing the dosage to 1500 mg/day in May 2003. This resulted in a reduction of the WBC count.
Imatinib mesylate now has been estimated to be used in about 3200 cases in Japan. According to a recent postmarketing surveillance by Novartis Japan, 24 cases of interstitial pneumonia, apparently related to imatinib, have been registered (20 cases of CML, one of hypereosinophilic syndrome, and three cases of gastrointestinal stromal tumor) (Novartis Pharma KK, data on file). Only two of 24 cases had a past history of lung disease; one was interstitial pneumonia and the other was chronic bronchitis. The appearance of interstitial pneumonia ranged from 10 to 337 days (median 42 days) after initiation of imatinib administration. Among these cases, three received 600 mg/day of imatinib, 13 cases received 400 mg/day, and eight cases less than 300 mg/day. In 20 CML patients showing interstitial pneumonia, 35% were in the accelerated/blastic crisis phase and 65% in the chronic phase. In the 14 cases reporting complete blood cell count and WBC differentiation, eight patients (57%) showed eosinophilia, although they had achieved complete hematological response by imatinib at that time. Steroid therapy was carried out in all these cases, and 19 cases recovered; one case did not improve, and one patient died.
The mechanism of drug-induced pneumonia is unclear in the vast majority of cases; however, it is considered to consist of either idiosyncratic ( ¼ noncytotoxic type) or cytotoxic type. The latter is dose dependent with pathologic features of interstitial edema, lymphocytic infiltration, destruction of alveolar epithelium etcetera, for example, busulfan lung or bleomycin lung. In contrast, the noncytotoxic type resembles hypersensitivity pneumonia, bronchiolitis obliterans, or eosinophilic pneumonia. We found eosinophilic infitration in the current case; however, we cannot completely rule out the possibility that the underlying disease (CML) may have modified the pathologic features. In the Novartis report, none of the seven cases of imatinib-induced interstitial pneumonia examined were DLST positive. In our case, the pathologic findings of TBLB showing prominent infiltration of eosinophils suggested an immunoallergic mechanism. There is one report showing a case of hypersensitivity pneumonitis related to imatinib, which may also support the immunoallergic background, but that study lacked pathologic corroboration. 4 Recently, Rosado et al 5 also reported a case of imatinib-induced interstitial pneumonia diagnosed by TBLB, but whose pathological findings were compatible with the nonspecific interstitial pneumonia without eosinophilic infiltration. The above data, taken together with our observations, suggest that imatinib-induced interstitial pneumonia may be heterogeneous and some of them may be likely to involve an immunoallergic mechanism. So far, the frequency of interstitial pneumonia related to imatinib appears to be relatively low and the underlying mechanism is still unclear; however, we must pay close attention to this adverse event.
T Yokoyama Chest CT performed before initiation and after cessation of imatinib mesylate. CT scans obtained at the level of bronchus intermedius (a) and lung bases (b) revealed reticular shadow and ground-glass opacities at subpleural area in both lung. CT scans obtained 18 days after discontinuation of imatinib mesylate at the level of bronchus intermedius (c) and lung bases (d) revealed that reticular shadow and ground-glass opacities almost disappeared.
Figure 2
Pathological findings of transbrochial lung biopsy. Alveolar structures were destroyed in most of the microscopic field in the TBLB specimen. Prominent infiltration of eosinophilic leukocytes (indicated by arrows) was observed in loose fibrous tissue. These findings are compatible with drug-induced interstitial pneumonia. (H-E stain, Â 400).
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